| Trial ID: | L4748 |
| Source ID: | NCT02753803
|
| Associated Drug: |
Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
|
| Title: |
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|DRUG: Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|DRUG: Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|DRUG: Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|DRUG: Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|DRUG: Evogliptin+Pioglitazone, Pioglitazone, Evogliptin
|
| Outcome Measures: |
Primary: AUC, area under the concentration-time curve, 1d~6d pre-dose, 15d~20d pre-dose, 29~34d pre-dose, 7d/21d/35d pre-dose and post-dose |
|
| Sponsor/Collaborators: |
Sponsor: Dong-A ST Co., Ltd.
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH
|
| Start Date: |
2016-07-27
|
| Completion Date: |
2017-03-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-09-18
|
| Locations: |
Clinical Trials Center, Seoul National University Hospital, Seoul, 03080, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02753803
|
